Diebold Nixdorf, Incorporated (DBD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$78.87
Price Target
$100.00
Target Range
$100.00 — $100.00
Analyst Rating
Buy
Forward P/E14.4x
Trailing P/E31.1x
Forward PEG—
Implied Growth+78.7%
Median Target$100.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$100
+26.8%
Consensus
$100
+26.8%
Bull Case
$100
+26.8%
DBD Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Diebold Nixdorf, Incorporated (DBD) has a Wall Street consensus price target of $100.00, based on estimates from 13 covering analysts. With the stock currently trading at $78.87, this represents a potential upside of +26.8%. The company has a market capitalization of $2.75B.
Analyst price targets range from a low of $100.00 to a high of $100.00, representing a 0% spread in expectations. The median target of $100.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DBD trades at a trailing P/E of 31.1x and forward P/E of 14.4x. Analysts expect EPS to grow +78.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Technology stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+31.9%
Avg Forward P/E15.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NATLNCR Atleos Corporation | $3.3B | $44.26 | $50.40 | +13.9% | Hold | 9.1x | 4 |
 PAXPatria Investments Limited | $1.9B | $12.04 | $18.00 | +49.5% | Buy | 8.4x | 5 |
 FISFidelity National Information Services, Inc. | $24.5B | $47.25 | $67.38 | +42.6% | Buy | 7.5x | 37 |
 FISVFiserv, Inc. | $30.4B | $56.81 | $74.64 | +31.4% | Buy | 7.0x | 60 |
 MAMastercard Incorporated | $443.4B | $500.94 | $656.87 | +31.1% | Buy | 25.5x | 64 |
 VVisa Inc. | $616.4B | $321.32 | $362.45 | +12.8% | Buy | 24.6x | 61 |
 JKHYJack Henry & Associates, Inc. | $10.6B | $146.03 | $203.75 | +39.5% | Buy | 21.8x | 22 |
 NTAPNetApp, Inc. | $22.4B | $113.00 | $120.50 | +6.6% | Hold | 14.2x | 70 |
 TOSTToast, Inc. | $15.4B | $29.36 | $39.76 | +35.4% | Buy | 23.7x | 29 |
 FOURShift4 Payments, Inc. | $4.3B | $46.86 | $73.36 | +56.6% | Buy | 8.4x | 29 |
Upside Potential Comparison
FOURPAXFISJKHYTOSTFISVMANATLSee DBD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DBD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DBD vs NVDA
Side-by-side business, growth, and profitability comparison vs NVIDIA Corporation.
Start ComparisonDBD — Frequently Asked Questions
Quick answers to the most common questions about buying DBD stock.
What is the DBD stock price target for 2026?
The consensus Wall Street price target for DBD is $100, representing 26.8% upside from the current price of $78.87. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is DBD a buy, sell, or hold?
DBD has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $100 implies 26.8% upside from current levels.
Is DBD stock overvalued or undervalued?
With a forward P/E of 14.3748x, DBD trades at a relatively low valuation. The consensus target of $100 implies 26.8% appreciation, suggesting meaningful undervaluation.
How high can DBD stock go?
The most bullish Wall Street analyst has a price target of $100 for DBD, while the most conservative target is $100. The consensus of $100 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover DBD stock?
DBD is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DBD stock forecast?
The 12-month DBD stock forecast based on 13 Wall Street analysts shows a consensus price target of $100, with estimates ranging from $100 (bear case) to $100 (bull case). The median consensus rating is "Buy".
What is DBD's forward P/E ratio?
DBD trades at a forward P/E ratio of 14.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy DBD stock?
Wall Street analysts are very optimistic on DBD, with a "Buy" consensus rating and $100 price target (26.8% upside). 5 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DBD price targets vary so much?
DBD analyst price targets range from $100 to $100, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $100 consensus represents the middle ground.